FY2017 Earnings Forecast for Sanofi Issued By Leerink Swann (SNY)
Sanofi (NYSE:SNY) – Analysts at Leerink Swann cut their FY2017 earnings per share estimates for shares of Sanofi in a note issued to investors on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings of $3.17 per share for the year, down from their previous estimate of $3.23. Leerink Swann also issued estimates for Sanofi’s Q4 2017 earnings at $0.68 EPS.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The company’s revenue was down 2.3% compared to the same quarter last year.
Several other equities research analysts have also recently weighed in on the company. Argus reiterated a “buy” rating and issued a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. BidaskClub cut Sanofi from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $53.50.
Shares of Sanofi (SNY) opened at 49.62 on Tuesday. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.65. The company has a 50-day moving average price of $49.54 and a 200-day moving average price of $48.38. The stock has a market cap of $124.62 billion, a price-to-earnings ratio of 11.52 and a beta of 0.87.
In related news, major shareholder Sanofi purchased 105,820 shares of Sanofi stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.00% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pennsylvania Trust Co raised its position in shares of Sanofi by 0.4% in the 2nd quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after acquiring an additional 37 shares in the last quarter. Moors & Cabot Inc. increased its position in Sanofi by 0.7% during the 2nd quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock valued at $311,000 after buying an additional 43 shares in the last quarter. Rehmann Capital Advisory Group increased its position in Sanofi by 0.7% during the 2nd quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after buying an additional 47 shares in the last quarter. Strategic Global Advisors LLC increased its position in Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after buying an additional 54 shares in the last quarter. Finally, First City Capital Management Inc. increased its position in Sanofi by 0.3% during the 2nd quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock valued at $1,839,000 after buying an additional 100 shares in the last quarter. 9.35% of the stock is owned by hedge funds and other institutional investors.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.